D'heygere, François <br/><br/>
SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.  [electronic resource] 

 -  Annals of hepatology   
 - 303-4 p.  digital 
<br/><br/> Publication Type: Letter; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1665-2681 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--therapeutic use<br/>Cohort Studies<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C--blood<br/>Humans<br/>Interferon-alpha--therapeutic use<br/>International Cooperation<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--therapeutic use<br/>Pragmatic Clinical Trials as Topic<br/>RNA, Viral--blood<br/>Recombinant Proteins--therapeutic use<br/>Ribavirin--therapeutic use<br/>Treatment Outcome<br/>Viral Load